Alzheimer’s disease is degenerative, meaning every day counts for retaining cognitive function and independence. That core truth is behind a bipartisan proposal asking Congress to expand Americans’ access to diagnostic tools for Alzheimer’s disease and related dementias. The Alzheimer’s Screening and Prevention Act — poignantly shorthanded “ASAP” — reflects growing recognition that early detection is essential to slowing disease progression.
Detecting Disease Before Symptoms Advance
Alzheimer’s begins to deteriorate brain function and attack cognition quietly, often years before patients receive imaging tests— which often occurs after behavior starts to change. Newly developed diagnostic technologies can test for biomarkers in the blood, shifting care toward earlier screening, diagnosis and intervention.
If Alzheimer’s can be identified prior to noticeable symptoms, patients can play an active role in figuring out how to move forward. Whether that be through treatment or other lifestyle modifications, understanding the full picture allows patients to make informed decisions. Broader access to blood tests could mean managing the disease from its onset, rather than scrambling to address cognitive decline after it emerges.
Removing Barriers to Preventive Services
Currently, extending Medicare coverage to new preventive services requires a specific act of Congress or a recommendation from the U.S. Preventive Services Task Force. This cost-conscious barrier blocks patient access to emerging diagnostic tests, even when the FDA has already endorsed them. The ASAP Act would empower the Secretary of Health and Human Services to give Medicare beneficiaries access to FDA-approved biomarker tests for early detection of Alzheimer’s. Anything less systematically excludes Medicare patients from life-extending scientific advancement.
Bringing Modern Diagnostics to More Patients
A patient who is diagnosed early can get treatment when it is most effective, participate fully in informed decision making, and possibly preserve their memories and personalities years longer than those diagnosed later. The ASAP Act represents both an exciting move toward preventive neurological care and a rare point of agreement in a divided political landscape.
